MARCH5 Promotes Cardiac Hypertrophy by Regulating Akt/mTOR/Gsk‐3β/GATA4 Signalling Pathway
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Guoyong Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Cardiomegaly, Glycogen Synthase Kinase 3 beta, GATA4 Transcription Factor, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan Science and Technology Program.
Abstract (Originalsprache)
This study aims to elucidate the role of MARCH5 in cardiac hypertrophy, thereby providing a theoretical foundation for novel therapeutic strategies for cardiac hypertrophy and heart failure. The expression of MARCH5 in cardiac hypertrophy models was assessed using immunohistochemistry, western blot (WB) and RT‐qPCR. Gain‐ and loss‐of‐function experiments of MARCH5 in cardiac hypertrophy were conducted both in vitro and in vivo. WB, RT‐qPCR, co‐immunoprecipitation (CoIP), immunohistochemistry and immunofluorescence were performed to investigate the molecular mechanisms of MARCH5. MARCH5 expression was upregulated in hypertrophied myocardium. Ang II stimulation resulted in increased expression of MYH7, BNP and cardiomyocyte area. These effects were aggravated by MARCH5 overexpression but antagonised by MARCH5 knockdown. MARCH5 heterozygous (MARCH5 +/− ) mice subjected to transverse aortic constriction (TAC) demonstrated alleviation of cardiac hypertrophy and improvement in cardiac function, whereas MARCH5 overexpression aggravated hypertrophy and cardiac dysfunction. Mechanistic studies indicated that MARCH5 directly interacted with Akt, enhancing the phosphorylation of Akt, mTOR and Gsk3β, thereby increasing GATA4 expression and aggravating cardiac hypertrophy. Our findings suggest that MARCH5 participates in the pathological cardiac hypertrophy by regulating the Akt/mTOR/Gsk‐3β/GATA4 pathway, positioning it as a promising therapeutic target for cardiac hypertrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
- Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China.
- Cardiac Structure and Function Research Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Fengming Wu, Yanbiao Liao
Förderung
- National Natural Science Foundation of China
- Sichuan Science and Technology Program
Zitieren
APA
Li, G., Wu, F., Lei, F., Zhang, J., & Liao, Y. (2025). MARCH5 Promotes Cardiac Hypertrophy by Regulating Akt/mTOR/Gsk‐3β/GATA4 Signalling Pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70735
Vancouver
Li G, Wu F, Lei F, Zhang J, Liao Y. MARCH5 Promotes Cardiac Hypertrophy by Regulating Akt/mTOR/Gsk‐3β/GATA4 Signalling Pathway. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70735
BibTeX
@article{Li2025,
author = {Li, Guoyong and Wu, Fengming and Lei, Fan and Zhang, Jialiang and Liao, Yanbiao},
title = {MARCH5 Promotes Cardiac Hypertrophy by Regulating Akt/mTOR/Gsk‐3β/GATA4 Signalling Pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70735}
}
EUVIMED